Argenx
Healthcare & Life Sci
Company overview
Argenx develops antibody therapies for autoimmune diseases and cancer. Its main product, Efgartigimod, is marketed as VYVGART and treats generalized myasthenia gravis. It also develops Empasiprubart for severe IgM-driven autoimmune diseases.
Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier founded Argenx in 2008. The company trades on Euronext Brussels under ARGX and on NASDAQ. It has 1,863 employees and reported €4.2 billion in revenue for 2025. Historically, the median salary is ~$218,500. Argenx is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- Ghent, Belgium